Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma

被引：0
|
作者：
Esteban-Fabro, Roger [1 ]
Willoughby, Catherine E. [1 ]
Pique-Gili, Marta [1 ]
Peix, Judit [1 ]
Montironi, Carla [1 ]
Abril-Fornaguera, Jordi [1 ]
Torrens, Laura [1 ]
Pinyol, Roser [1 ]
Llovet, Josep M. [1 ,2 ,3 ]
机构：
[1] Liver Canc Translat Res Lab, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Liver Unit, Barcelona, Spain
[2] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Tisch Canc Inst, New York, NY USA
[3] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AS053
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] REPROGRAMMING THE INTRAHEPATIC CHOLANGIOCARCINOMA IMMUNE MICROENVIRONMENT BY CHEMOTHERAPY AND CTLA-4 BLOCKADE ENHANCES ANTI-PD1 THERAPY
    Chen, Jiang
    Amoozgar, Zohreh
    Liu, Xin
    Aoki, Shuichi
    Liu, Zelong
    Matsui, Aya
    Pu, Zhangya
    Halvorsen, Stefan
    Lei, Pin-Ji
    Ho, Won Jin
    Huang, Peigen
    Jain, Rakesh
    Bardeesy, Nabeel M.
    Duda, Dan G.
    HEPATOLOGY, 2023, 78 : S106 - S107
  • [42] Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
    Chao Gao
    Shenghao Wang
    Weiqing Shao
    Yu Zhang
    Lu Lu
    Huliang Jia
    Kejin Zhu
    Jinhong Chen
    Qiongzhu Dong
    Ming Lu
    Wenwei Zhu
    Lunxiu Qin
    Frontiers of Medicine, 2022, 16 (03) : 467 - 482
  • [43] EGFR mutations are associated with unfavourable efficacy to anti-PD1 therapy in NSCLC
    Liu, S-Y.
    Dong, Z.
    Zhong, W-Z.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
    Gao, Chao
    Wang, Shenghao
    Shao, Weiqing
    Zhang, Yu
    Lu, Lu
    Jia, Huliang
    Zhu, Kejin
    Chen, Jinhong
    Dong, Qiongzhu
    Lu, Ming
    Zhu, Wenwei
    Qin, Lunxiu
    FRONTIERS OF MEDICINE, 2022, 16 (03) : 467 - 482
  • [45] Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
    Chao Gao
    Shenghao Wang
    Weiqing Shao
    Yu Zhang
    Lu Lu
    Huliang Jia
    Kejin Zhu
    Jinhong Chen
    Qiongzhu Dong
    Ming Lu
    Wenwei Zhu
    Lunxiu Qin
    Frontiers of Medicine, 2022, 16 : 467 - 482
  • [46] Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
    Hou, Shihe
    Grigorian, Berta
    Schmid, Anita
    Desai, Neil
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Decision tree model with tumor immune function genes for predicting response to anti-PD1 therapy in renal cell carcinoma.
    Bi, Xingang
    Luo, Zhiwen
    Bi, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and advanced breast cancer
    Chen, I-Chun
    Lin, Ching-Hung
    Chang, Dwan-Ying
    Chen, Tom Wei-Wu
    Wang, Ming-Yang
    Ma, Wei-Li
    Lin, Yi-Ting
    Huang, Shu-Min
    Hsu, Chia-Lang
    Lu, Yen-Shen
    CELL REPORTS MEDICINE, 2025, 6 (01)
  • [49] Anti-GITR with Radiation Therapy Enhances Anti-Tumor Abscopal Effects in Anti-PD1 Resistant Murine Model
    Cushman, T. R.
    Schoenhals, J.
    Barsoumian, H.
    Caetano, M. D. S.
    Cadena, A.
    Younes, A.
    Li, A.
    Niknam, S.
    Cortez, M. A.
    Welsh, J. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S153 - S153
  • [50] In vivo activity of combinations of cytotoxic regimens with anti-PD1 and anti-PDL1 in various syngeneic cancer models
    Grasselly, Chloe
    Denis, Morgane
    Bourguignon, Aurore
    Talhi, Nolan
    Tourette, Anne
    Mathe, Doriane
    Serre, Laurent
    Jordheim, Lars Petter
    Dumontet, Charles
    CANCER RESEARCH, 2018, 78 (13)
12345